Lung Cancer Trials Ask AI to find trials
RecruitingPhase 1NCT06917079
Official study title

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Study summary

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedBBO-11818 and Pembrolizumab

Plus 9 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · KRAS · Early-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 2, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1

Interventional

Where is it offered?17 U.S. locations

Locations may change over time.

Who runs it?TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Interventions being studied
Drug: BBO-11818; Drug: Pembrolizumab; Drug: Platinum chemotherapy (cisplatin or carboplatin); Drug: Pemetrexed; Drug: Cetuximab; Drug: mFOLFOX6; Drug: mFOLFOX6; Drug: BBO-10203; Drug: mFOLFIRINOX; Drug: Gemcitabine; Drug: Nab-paclitaxel
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Early-stage or resectable→Locally advanced→Metastatic or stage IV→
Biomarkers
KRAS→
Treatment approach
Immunotherapy→Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation
  • Measurable disease by RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
  • Life expectancy \>24 weeks
  • Adequate organ function
Reasons someone may not be able to joinExclusion criteria
  • Malignancy within the last 2 years as specified in the protocol
  • Untreated brain metastases Other inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • The Angeles Clinic and Research Institute - West Los Angeles OfficeLos Angeles, California
  • University of California DavisSacramento, California
  • University of California San Diego Moores Cancer CenterSan Diego, California
  • University of California San Francisco Helen Diller Family Comprehensive Cancer CenterSan Francisco, California
  • Yale UniversityNew Haven, Connecticut
  • Moffitt Cancer CenterTampa, Florida
  • OSF Healthcare Cancer InstitutePeoria, Illinois
  • Massachusetts General HospitalBoston, Massachusetts
  • NYU Langone HealthNew York, New York
  • Columbia University Irving Medical CenterNew York, New York
  • Vanderbilt University Medical CenterNashville, Tennessee
  • Sarah Cannon Research Institute at Mary CrowleyDallas, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 2, 2026. Always confirm current availability with the study team.

View original record ↗